Die Suchmaschine für Unternehmensdaten in Europa
EU-Förderung (2.694.377 €): Austausch und Wiederverwendung von Daten aus klinischen Studien zur Maximierung der Wirkung Hor 29.06.2023 EU-Rahmenprogramm für Forschung und Innovation "Horizont"
Auf einen Blick
Text
Austausch und Wiederverwendung von Daten aus klinischen Studien zur Maximierung der Wirkung
Data from clinical trials are a rich source of clinical information, highly structured and clearly explained by the accompanying protocols. Responsible sharing of such data holds incredible promises to increase value and decrease waste in medical research. It is built on principles (ethical, scientific), governance structures, skills, and operation infrastructure. Clinical trial data sharing (CTDS) is an emerging activity in academia as well as in the pharmaceutical industry. Both communities develop models for organising and performing CTDS. Thereby, several issues gain relevance: enhancing data sharing with researchers, improving public access to clinical study information, sharing results with patients participating in clinical trials, certifying procedures for sharing clinical trial information, and reaffirming commitments to publish clinical trial results. We see a developing field of professional activities that need well educated experts to define and implement best practices. Training such a new generation of experts in CTDS requires specific teachings with a focus on clinical trial transparency and reproducible research practices. It should include topics such as clinical trials regulations, ethical, legal, and social issues, informatics, data science, biostatistics, and meta-research, as well as domain expertise across different medical fields. In order to gain a deep understanding of this developing field, research activities should be based on meta-research approaches. Those activities focus on research on best practices for CTDS, developing methods to make efficient use of shared data (e.g., methods to augment randomised clinical trials, perform independent participant data meta-analysis, or estimate personalised treatment effects) and measuring CTDS impact.
Geförderte Unternehmen:
| Firmenname | Förderungssumme |
| Bayer AG | ? |
| Charite - Universitaetsmedizin Berlin | 521.078 € |
| Hospices Civils de Lyon | 282.694 € |
| Ludwig-Maximilians-Universitaet Muenchen | 260.539 € |
| Medizinische Universitaet Wien | 270.331 € |
| Universita Degli Studi Di Padova | 259.438 € |
| Universitaetsmedizin Goettingen - Georg-August-Universitaet Goettingen - Stiftung Oeffentlichen Rechts | 260.539 € |
| Universitair Medisch Centrum Utrecht | 274.370 € |
| Universite de Rennes | 565.387 € |
Quelle: https://cordis.europa.eu/project/id/101120360
Diese Bekanntmachung wurde von Englisch nach Deutsch übersetzt. Die Bekanntmachung bezieht sich auf einen vergangenen Zeitpunkt, und spiegelt nicht notwendigerweise den heutigen Stand wider. Der letzte verfügbare Stand wird auf folgender Seite wiedergegeben: Bayer AG, Leverkusen.